Lilly Doesn’t Expect to Meet Demand for Obesity Drugs This Year

Eli Lilly & Co. doesn’t expect to meet soaring demand for weight-loss and diabetes drugs this year or maybe not even by 2025, Chief Financial Officer Anat Ashkenazi told investors at the TD Cowen annual health-care conference.

• Ashkenazi said Wednesday that Lilly is undertaking the most ambitious expansion agenda in its history, but that production capacity will still take some time to come online
• NOTE: Lilly introduced Zepbound for obesity late last year; its diabetes drug Mounjaro, which is also commonly used for weight loss, has repeatedly fallen into short supply, as have competing medicines from Novo Nordisk A/S

To ...